ND

Medical Policies

Print

Policy Number:	S-123		
Policy Name:	Lung and Lobar Lung Transplant		
Policy Type:	Medical	**Policy Subtype:**	Surgery
Effective Date:	09-15-2025	**End Date:**	11-02-2025

Description

A lung transplant consists of replacing all or part of diseased lungs with healthy lung(s) or lobes. Transplantation is an option for individuals with end-stage lung disease.

Diagnosis Codes

A15.0	C96.5	C96.6	D48.2	D86.0	D86.2	E71.39
E80.3	E84.0	E84.11	E84.19	E84.8	E84.9	E88.01
I26.01	I26.02	I26.09	I26.90	I26.92	I26.93	I26.94
I26.99	I27.0	I27.22	I27.82	I27.83	I27.89	J42
J43.0	J43.1	J43.2	J43.8	J43.9	J44.0	J44.81
J44.89	J44.9	J47.0	J47.1	J47.9	J84.1	J84.112
J84.178	M34.0	M34.81	P27.0	P27.1	P27.8	P27.9
Q33.4	T86.811					

CURRENT CODING

CPT:

32850	DONOR PNEUMONECTOMY FROM CADAVER DONOR	Commercial
32851	LUNG TRANSPLANT 1 W/O CARDIOPULMONARY BYPASS	Commercial
32852	LUNG TRANSPLANT 1 W/CARDIOPULMONARY BYPASS	Commercial
32853	LUNG TRANSPLANT 2 W/O CARDIOPULMONARY BYPASS	Commercial
32854	LUNG TRANSPLANT 2 W/CARDIOPULMONARY BYPASS	Commercial
32855	BKBENCH PREPJ CADAVER DONOR LUNG ALLOGRAFT UNI	Commercial
32856	BKBENCH PREPJ CADAVER DONOR LUNG ALLOGRAFT BI	Commercial
32850	DONOR PNEUMONECTOMY FROM CADAVER DONOR	Medicaid Expansion
32851	LUNG TRANSPLANT 1 W/O CARDIOPULMONARY BYPASS	Medicaid Expansion
32852	LUNG TRANSPLANT 1 W/CARDIOPULMONARY BYPASS	Medicaid Expansion
32853	LUNG TRANSPLANT 2 W/O CARDIOPULMONARY BYPASS	Medicaid Expansion
32854	LUNG TRANSPLANT 2 W/CARDIOPULMONARY BYPASS	Medicaid Expansion
32855	BKBENCH PREPJ CADAVER DONOR LUNG ALLOGRAFT UNI	Medicaid Expansion
32856	BKBENCH PREPJ CADAVER DONOR LUNG ALLOGRAFT BI	Medicaid Expansion

HCPCS:

S2060	Lobar lung transplantation	Commercial
S2061	Donor lobectomy (lung)	Commercial
S2060	Lobar lung transplantation	Medicaid Expansion
S2061	Donor lobectomy (lung)	Medicaid Expansion

References

1. Spratt JR, Brown RZ, Rudser K, et al. Greater survival despite increased complication rates following lung transplant for alpha-1-antitrypsin deficiency compared to chronic obstructive pulmonary disease. *J Thorac Dis*. 2019;11(4):1130-1144.
2. Black CK, Termanini KM, Aguirre O, et al. Solid organ transplantation in the 21st century*. Ann Transl Med.* 2018;6(20):409.
3. Organ Procurement and Transplantation Network (OPTN). Policy 10: Allocation of Lungs. Updated March 16, 2023; https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf. Accessed December 6, 2023.
4. Paraskeva MA, Edwards LB, Levvey B, et al. Outcomes of adolescent recipients after lung transplantation: An analysis of the International Society for Heart and Lung Transplantation R *J Heart Lung Transpl*. 2018;37(3):323-331.
5. Yu H, Bian T, Yu Z, et al. Bilateral lung transplantation provides better long- term survival and pulmonary function than single lung transplantation: A systematic review and meta-analysis. *Transpl*. 2019;103(12):2634-2644.
6. Biswas Roy S, Panchanathan R, Walia R, et al. Lung retransplantation for chronic rejection: A single-center experience. *Ann Thorac Surg*. 2018;105(1):221-227.
7. Jones JM, Kracalik I, Levi ME, et al. Assessing solid organ donors and monitoring transplant recipients for human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection - U.S. public health service guideline, 2020. *MMWR Recomm Rep.* 2020;69(4):1-16.
8. Centers for Medicare & Medicaid. Transplant. Updated December 12,2021; https://www.cms.gov/Medicare/Provider-Enrollment- and Certification/CertificationandComplianc/Transplant.html.
9. Yu X, Li X, Wang L et al. Pulmonary rehabilitation for exercise tolerance and quality of life in IPF patients: A systematic review and meta-analysis. *Biomed Res Int.* 2019;2019:8498603.
10. Cheng L, Tan B, Yin Y et al. Short- and long-term effects of pulmonary rehabilitation for idiopathic pulmonary fibrosis: A systematic review and meta- analysis. *Clin Rehabil*. 2018;32(10).
11. Leard LE, Holm AM, Valapour M, et al. Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant*. 2021;40(11):1349- 1379.
12. United Network for Organ Sharing (UNOS). Transplant trends. Updated June 14, 2023; https://unos.org/data/transplant-trends/. Accessed December 06, 2023.
13. Kapila N, Menon KVN, Al-Khalloufi K, et al. Hepatitis C virus NAT-positive solid organ allografts transplanted into hepatitis C virus-negative recipients: A real-world experience. *Hepatology*. 2020;72(1):32-41.
14. Cypel M, Feld JJ, Galasso M, et al. Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: An open-label, single- centre, pilot trial. *Lancet Respir Med*. 2020;8(2):192-201.
15. Woolley AE, Singh SK, Goldberg HJ, et al. Heart and lung transplants from HCV-infected donors to uninfected recipients. *N Engl J Med*. 2019;380(17):1606-1617.
16. Feld JJ, Cypel M, Kumar D, et al. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: A phase 3, single-centre, open-label study. *Lancet Gastroenterol Hepatol*. 2020;5(7):649-657.
17. Koval CE, Farr M, Krisl J, et al. Heart or lung transplant outcomes in HIV- infected recipients. *J Heart Lung Transplant*. 2019;38(12):1296-1305.
18. Silva, JS, Olland A, Massard G, Falcoz PE. Does lobar or size-reduced lung transplantation offer satisfactory early and late outcomes? *Interact Cardiovasc Thorac Surg*. 2020;31(1):93-97.
19. Inci I, Schuurmans MM, Caviezel C, et al. Long-term outcomes of cadaveric lobar lung transplantation: An important surgical option. *Ann Thorac Cardiovasc Surg*. 2021;27(4):244-250.

20. Ahmad K, Pluhacek JL, Brown AW, et al. Ex vivo lung perfusion: A review of current and future application in lung transplantation. *Pulm Ther*. 2022;8(2):149-165
21. Li D, Liu Y, Wang B, et al. Single versus bilateral lung transplantation in idiopathic pulmonary fibrosis: A systematic review and meta-analysis. PLoS One. 2020;15(5):e0233732.
22. Taweesedt P, Lertjitbanjong P, Eksombatchai D, et al. Impact of antifibrotic treatment on postoperative complications in patients with interstitial lung diseases undergoing lung transplantation: A systematic review and meta- analysis. *J Clin Med.* 2023;12(2):655.

ND Committee Review

Internal Medical Policy Committee 1-19-2021 Annual Review - *Effective March 01, 2021*

- No changes in criteria

Internal Medical Policy Committee 11-29-2022 Annual Review - *Effective January 02, 2023*

- *Updated* Professional Statement and Societal Positions

Internal Medical Policy Committee 11-15-2023 Coding Update - *Effective October 01, 2023*

- *Added* Diagnosis codes J44.81; and J44.89; and
- *Removed* Diagnosis code D48.1

Internal Medical Policy Committee 1-16-2024 Revision with coding update - *Effective March 04, 2024*

- *Added* diagnosis codes J84.112, J84.178, and T86.811; and
- *Added* HIV criteria

Disclaimer

Current medical policy is to be used in determining a Member's contract benefits on the date that services are rendered. Contract language, including definitions and specific inclusions/exclusions, as well as state and federal law, must be considered in determining eligibility for coverage. Members must consult their applicable benefit plans or contact a Member Services representative for specific coverage information. Likewise, medical policy, which addresses the issue(s) in any specific case, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and the Company reserves the right to review and update medical policy periodically.